anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Regulatory T cells (Tregs) are crucial in regulating T-cell-mediated immune responses. Numerous studies have shown that dysfunction or decreased numbers of Tregs may be involved in inflammatory cardiovascular diseases (CVDs) such as atherosclerosis, hypertension, myocardial infarction, myocarditis, cardiomyopathy, valvular heart diseases, heart failure, and abdominal aortic aneurysm. Tregs can help to ameliorate CVDs by suppressing excessive inflammation through various mechanisms, including inhibition of T cells and B cells, inhibition of macrophage-induced inflammation, inhibition of dendritic cells and foam cell formation, and induction of anti-inflammatory macrophages. Enhancing or restoring the immunosuppressive activity of Tregs may thus serve as a fundamental immunotherapy to treat hypertension and CVDs. However, the precise molecular mechanisms underlying the Tregs-induced protection against hypertension and CVDs remain to be investigated. This review focuses on recent advances in our understanding of Tregs subsets and function in CVDs. In addition, we discuss promising strategies for using Tregs through various pharmacological approaches to treat hypertension and CVDs.
Salmonella infection, also known as Salmonellosis, is one of the most common food-borne illnesses. Salmonella infection can trigger host defensive functions, including an inflammatory response. The provoked-host inflammatory response has a significant impact on the bacterial population in the gut. In addition, Salmonella competes with other gut microorganisms for survival and growth within the host. Compositional and functional alterations in gut bacteria occur because of the host immunological response and competition between Salmonella and the gut microbiome. Host variation and the inherent complexity of the gut microbial community make understanding commensal and pathogen interactions particularly difficult during a Salmonella infection. Here, we present metabolomics and lipidomics analyses along with the 16S rRNA sequence analysis, revealing a comprehensive view of the metabolic interactions between the host and gut microbiota during Salmonella infection in a CBA/J mouse model. We found that different metabolic pathways were altered over the four investigated time points of Salmonella infection (days -2, +2, +6, and +13). Furthermore, metatranscriptomics analysis integrated with metabolomics and lipidomics analysis facilitated an understanding of the heterogeneous response of mice, depending on the degree of dysbiosis.
OBJECTIVE: To assess the association between coronary collateral circulation and ventricular contractile function in patients with non-reperfused acute myocardial infarction.
METHOD: A retrospective and descriptive clinical study was conducted on patients with ST-elevation myocardial infarction (STEMI) at a reference cardiovascular center, from January 2006 to December 2022. Coronary angiographies and echocardiograms were reviewed to evaluate coronary collateral circulation and ventricular function, respectively. Patients were divided into groups based on the presence of collateral circulation. Both groups were compared and mortality during the index hospitalization was analyzed.
RESULTS: Out of a total of 14,985 patients with acute coronary syndrome, 8134 (54.3%) had the diagnosis of STEMI. We excluded 12,880, leaving a total of 2105 non-reperfused STEMI patients who underwent coronary angiography, revealing lesions. There were more patients without collateral circulation: 1547 (73.5%) vs. 558 (26.5%) (p = 0.025). Patients without collateral circulation had a higher left ventricular ejection fraction (median of 47% vs. 42%; p < 0.001). Mortality in patients with collateral circulation was higher compared to those without it (11.6% vs. 9.8%; p = 0.225), but statistical significance was not reached.
CONCLUSIONS: Non-reperfused STEMI patients did not show protection from collateral circulation when assessing left ventricular systolic function. We did not find a difference in mortality compared to the population without development of collateral circulation.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
Processes for making microparticles, preferably containing an active agent, are provided. In a preferred embodiment, the process involves preparing (1) a dispersed phase containing an agent in a solution of polymer and a first solvent; (2) a continuous phase containing a surfactant, a second solvent that is totally or partially immiscible with the first solvent, and sufficient first solvent to saturate the continuous phase; and (3) an extraction phase that is a nonsolvent for the polymer, a solvent for the continuous phase components, and a solvent for the first solvent, wherein the first solvent has solubility in the extraction phase of between about 0,1 % and 25 % by weight. Then, the dispersed phase and the continuous phase are mixed to form an emulsion, and the emulsion is then briefly mixed with a suitable quantity of extraction phase to induce skin formation at the interface of the dispersed and continuous phases. Remaining solvent is removed by an evaporation process step. The emulsification and solvent removal steps are preferably conducted in a continuous process. The brief extraction step prior to evaporation minimizes the loss of active agent from the microparticles, and reduces the required volume of extraction phase as compared to other extraction-based processes. Alternate emulsification methods and solvent removal methods, such as incremental extraction, cryogenic extraction, or membrane separation, also are provided, and can be used in various combinations to make microparticles.
PURPOSE:To obtain an adsorbent capable of selectively adsorbing immunoglobulin, in particular, gamma-globulin in larger quantities than the case with conventional adsorbents by immobilizing chitosan onto a carrier consisting of a polysulfone resin. CONSTITUTION:A carrier consisting of a polysulfone resin, pref. a porous membrane (esp. 0.1-1mum in pore size and 0.1-0.3mm in thickness) is immersed in an aqueous alcohol solution, taken out and then immediately immersed in water for setting treatment. The resulting wet carrier is brought into contact with an aqueous chitosan solution (pref. 0.1-0.5wt.% in concentration), and then once dried and brought into contact with a basic aqueous solution, washing and then drying, thus obtaining the objective adsorbent for immunoglobulin. Immobilization of immunoglobulin onto this adsorbent can provide the objective adsorbent for antigen with higher antigen-adsorbability compared to conventional ones.
A high affinity targeted Trop2 multi-cyclic peptide molecular framework belongs to the technical field of biology. Ligand screening is carried out on human trophoblast surface glycoprotein antigen 2 (Trop 2) by utilizing phage display polycyclic peptide library, and a series of polycyclic peptide molecular frameworks capable of combining with Trop2 with high affinity are obtained. On the basis, the obtained specific cyclopeptide ligand is further optimized, so that more polypeptide ligands with pharmaceutical properties are obtained. Can be used for constructing various polypeptide-drug coupling bodies and provides a targeting recognition element for developing a novel disease diagnosis and treatment method. The advantage of CPPC motif orthogonal pairing is utilized to obtain the multi-element cyclic peptide with obvious oxidation main product and structural rigidity. Compared with the common linear peptide and unit cyclic peptide, the constructed multi-membered cyclic peptide has larger binding interface, more complex rigid structure and better binding affinity with a target.
All patients receive a frailty assessment within 7 days before initiating the first cycle of palliative chemotherapy, followed by geriatric intervention. Patients exhibiting impairments in at least two dimensions are considered frail. The frail group will receive management and recommendations based on the specific impairment domain.
The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in the periplasm of gram negative bacteria and mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the outer surface-expression of ligand fusion proteins employed with phage display. The inventors have also provided improved antobodies that were initially prepared using the sceening methods developed.
Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
Lipid nanoformulations of BET inhibitors for the treatment of kidney damage. In situations of acute and chronic kidney damage, BET (Bromodomain and Extra Terminal domain) inhibitors, such as the JQ1 molecule, can be used to inhibit the UPR (Unfolded Protein Response) pathway and other inflammatory and pro-fibrotic pathways, causing tissue damage to improve. and kidney function recovers. However, JQ1 presents toxicity and low specificity, so to achieve an adequate therapeutic effect, it is necessary to use high doses that are incompatible with a low degree of toxicity. In the present invention, a solution to the poor pharmacokinetic profile of JQ1 and its low oral availability is proposed, which consists of the design and development of lipid-based nanoparticles that allow the JQ1 inhibitor to be selectively encapsulated and administered in sufficient quantity to achieve the therapeutic effect. desired and, at the same time, reduce its toxicity.  (Machine-translation by Google Translate, not legally binding)
Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
This group received intravenous phenothiazine migraine treatment (dosage at physician discretion) plus oral dexamethasone 8mg at time of emergency department discharge. Patients and clinicians were blinded.
Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
The utility model relates to a health care eye patch which comprises a patch body which is covered on eyes and fixing bands. The health care eye patch is characterized in that the patch body comprises an outer cover and dressing bags which are respectively corresponding to a left eye and a right eye and enclosed in the outer cover. The outer cover is an interlayer bag which is composed of a surface layer and an inner layer, wherein the surface layer and the inner layer are fixedly connected. A left notch and a right notch are arranged on the upper edge of the outer cover, and the left notch and the right notch are respectively used for replacing the dressing bags. Medicine patches are arranged on one side, attaching to skin, of the inner layer, and are respectively corresponding to the left eye and the right eye. Magnetic stones and / or far infrared coating points are arranged on the side, attaching to the skin, of the inner layer, and are corresponding to circumferential portions of the left eye and the right eye. The dressing bags are hot compress bags, cold compress bags or medicine application bags, wherein heat emission dressing is enclosed in the hot compress bags, cooling dressing is enclosed in the cold compress bags, and medicine dressing is enclosed in the medicine application bags. The health care eye patch has the advantages that the dressing bags can be conveniently changed through the left notch and the right notch on the upper edge of the outer cover, the outer cover can be used repeatedly and continuously, different health care modes can be adopted according to needs of users by changing the dressing bags, and the health care eye patch achieves the effects of being simple in structure, multiple in function, convenient to operate, and saving materials.
In an educational intervention, participants complete a five question lymphedema survey, designed by the Occupational Therapy staff, as an instrument to assess a patient's knowledge of lymphedema signs/symptoms before surgery. An OT, PT, and/or CLT provide written handouts to participants on the pathophysiology, signs, symptoms, and treatment of lymphedema. Participants repeat the survey at 3 months post-surgery. BUE circumferential measurements are also collected before surgery and at 3 months post-surgery.
The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.
The Health Call study is divided into two phases. The first phase is a randomized controlled trial and side-by- side cost-benefit analysis. Enrolled guardians of pediatric patients will complete a questionnaire at the point of referral and then be randomized to intervention, the automated reminder system, or no reminder. The investigators will then monitor attendance status at their subsequent appointment and evaluate whether the appointment reminders affected attendance as well as the cost-benefit ratio of using the reminder system.

The second phase will involve interviewing guardians and healthcare professionals. These interviews have two foci. First, combined with patient, guardian, and/or household data from the randomized trial, these results will be used to develop a more comprehensive understanding of why pediatric patients attend appointments. The second focus is on improving the reminder system and developing new health technology interventions that can increase patient attendance.
A patient support apparatus includes a patient support surface to support a patient. The patient support surface has at least one air bladder that is inflated and/or deflated to achieve a turn assist function and/or a therapy function of the patient support surface. A graphical user interface (GUI) is configured to receive user inputs from a caregiver to initiate the turn assist or therapy functions. The patient support apparatus has control circuitry coupled to the GUI. The GUI is controlled by the control circuitry to display information indicating that the patient is improperly positioned on the patient support surface for either the turn assist function or the therapy function. Alternatively or additionally, the control circuitry indicates that the patient is improperly positioned for raising a head section of a bed frame.
CKD affects about 850 million people worldwide and is projected to be the fifth leading cause of death by 2040. Individuals from low- and middle-income countries (LMICs) bear the bulk of CKD. They face challenges including lack of awareness among the general population, as well as health care providers, unique risk factors such as genetic predispositions, infectious diseases, and environmental toxins, limited availability and affordability of diagnostic tests and medications, and limited access to KRTs. The inadequate health system infrastructure, human resources, and financing mechanisms to support comprehensive and integrated kidney care worsen the situation. Overcoming these challenges needs concerted efforts toward early detection, intervention, and multidisciplinary follow-up, policy, collaboration, advocacy, and financing. To achieve this, there is need for individual governments to include kidney health among the key health priorities and build capacity toward resilient health care systems. Integrating kidney care using the roadmaps of well-established management systems for other chronic diseases, such as HIV, has the potential to expedite the widespread adoption of kidney health. The aim of this article is to provide an overview of the current state and future prospects of kidney care in LMICs, highlighting the main challenges, ongoing efforts, and opportunities for improvement. We present case studies of exemplary efforts from three continents of the world with the highest densities of LMICs and propose potential strategies for a sustainable solution.
The present invention discloses a Chinese medicine preparation for treating perineum diseases for women. The present invention is provided by a famous Chinese medicine expert Mr Su yikang who thinks that the pathogenesis is caused by dryness, humidity and hotness, and people who study modern medicine think that local impurity is an important reason for causing gynecological diseases. Deficiency and excess are distinguished, and primary and secondary objects are marked. By combining clinical experiences, a choiceness prescription uses flavescent sophora roots, argyi leaves, cnidium fruit, alum, clove, borneol, pepper, dahurian angelica and asarum herb. The medicines are combined to be conventionally made into pants inner pads and sanitary towel inner pads, which have functions of eliminating dampness, alleviating pain, removing dampness to relieve itching, promoting urination, moistening, relieving inflammation, suppressing bacteria, promoting tissue regeneration, removing the necrotic tissue, softening and resolving hard mass, resisting inflammation, removing blood stasis and driving QI-blood circulation. The modern medicine research proves that the prescription can be used for preventing inflammation infiltration and improving ending blood circulation of the perineum skin. When heavy flavour of the medicines is sent out, effective ingredients quickly penetrate the skin pores, and impregnate into capillaries, and are absorbed by a human body to play the functions of antisepsis and anti-inflammation.
Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
Wind energy appears to place global environmental benefits against local human health, particularly sleep. The result is a significant challenge to wind-energy development for the achievement of large-scale alternative energy. Our purpose is to examine noise from wind turbines and its potential to disrupt sleep, to examine the human health literature addressing these concerns, and to provide insight into how developers and communities can employ these concepts to pursue wind energy without impacting human health. The latest and most rigorous research on noise from wind turbines points to healthy sleep, when turbines are sited reasonably. This includes audible noise, low-frequency noise, and infrasound. Recent advances in acoustical standards provide practical methods to ensure adherence to these scientific findings. There now exist key data concerning wind-turbine noise, and its impact on sleep. Knowing that information, and how to deploy it with modern engineering standards should simultaneously facilitate wind development and protect human health.
The research is a randomized controlled trial. The research was conducted with 124 primiparous pregnant women (intervention group n=62, control group n=62) who were hospitalized in the delivery unit of Aksaray Training and Research Hospital between September 2023 and January 2024. The pregnant women in the intervention group were given the intrapartum care model in line with WHO recommendations after cervical dilation reached 5 cm. The control group received only the standard intrapartum care in the hospital. Data were collected using the personal information form, labor and postpartum follow-up form, Visual Analog Scale (VAS), Labor Comfort Scale (DKS), Intrapartum Fear of Labor Scale, and Women's Perception of Supportive Care Given During Childbirth Scale. VAS, DKS, and Fear of Childbirth scale were applied to women in both groups when cervical dilation was 5 cm and 9 cm. After birth, the Women's Perception of Supportive Care Given During Childbirth scale was applied.
Described are adjuvants and medical products including such adjuvants having increased immunogenicity towards a particular antigen. In certain embodiments, the adjuvant includes a CpG oligonucleotide and a collagenous extracellular matrix (ECM) material, preferably in a synergistically effective amount. Medical products including at least one antigen derived from a bacterial pathogen and a collagenous ECM material are also described herein. Such medical products can further include a CpG oligonucleotide. Medical products as described herein can find use as a vaccine preparation to treat or prevent a medical condition, and preferably a medical condition caused by a bacterial pathogen. Related methods of manufacture and use are also described.
Uses an electrical stimulator that delivers stimulation to open the hand and extend the elbow repeatedly with preprogrammed timing and intensity. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.